Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives / statement of Mary Denigan-Macauley.

Format:

Book

Government document

Author/Creator:

United States. Government Accountability Office, author.

Denigan-Macauley, Mary, author.

Contributor:

United States. Congress. House. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, sponsoring body.

Series:

Testimony ; GAO-21-409T.

Testimony ; GAO-21-409T

Language:

English

Subjects (All):

United States. Food and Drug Administration--Rules and practice.

United States.

United States. Food and Drug Administration.

COVID-19 (Disease)--Treatment--United States.

COVID-19 (Disease).

COVID-19 Pandemic, 2020-2023--United States.

COVID-19 Pandemic, 2020-2023.

Drugs--Inspection--United States.

Drugs.

Drugs--United States--Safety measures.

Drug reimportation--United States.

Drug reimportation.

COVID-19 (Disease)--Treatment.

Drugs--Inspection.

Drugs--Safety measures.

Genre:

Rules

Physical Description:

1 online resource (18 pages) : color illustrations, color map.

Other Title:

Drug safety: Food and Drug Administration's future inspection plans to address issues presented by COVID-19 backlog

Place of Publication:

[Washington, D.C.] : United States Government Accountability Office, 2021.

Notes:

"For release on delivery, expected at 10:00 a.m. ET, Thursday, March 4, 2021."

Includes bibliographical references.

Description based on online resource, PDF version; title from cover (GAO, viewed Mar. 3, 2021).

OCLC:

1240422157